CLEC10A

Chr 17

C-type lectin domain containing 10A

Also known as: CD301, CLECSF13, CLECSF14, DC-ASGPR, HML, HML2, MGL

NCBI Gene: 10462ENSG00000132514UniProt: Q8IUN9

This gene encodes a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily. Members of this family share a common protein fold and have diverse functions, such as cell adhesion, cell-cell signalling, glycoprotein turnover, and roles in inflammation and immune response. The encoded type 2 transmembrane protein may function as a cell surface antigen. Two transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, Jul 2008]

61
ClinVar variants
19
Pathogenic / LP
0.00
pLI score
0
Active trials
Clinical Summary— CLEC10A
⚡
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
19 Pathogenic / Likely Pathogenic· 36 VUS of 61 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

gnomAD
Tolerant — LoF & missense variants common in population
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
1.14LOEUF
pLI 0.000
Z-score 1.18
OE 0.67 (0.41–1.14)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
0.36Z-score
OE missense 0.92 (0.81–1.05)
154 obs / 167.1 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.67 (0.41–1.14)
0≤0.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.92 (0.81–1.05)
0≤0.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.0.86
0≤1.21.6
LoF obs/exp: 10 / 14.9Missense obs/exp: 154 / 167.1Syn Z: 0.93

ClinVar Variant Classifications

61 submitted variants in ClinVar

ClinVar

Classification Summary

Pathogenic18
Likely Pathogenic1
VUS36
Likely Benign5
Benign1
18
Pathogenic
1
Likely Pathogenic
36
VUS
5
Likely Benign
1
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
18
0
18
Likely Pathogenic
0
0
1
0
1
VUS
0
29
7
0
36
Likely Benign
0
5
0
0
5
Benign
0
1
0
0
1
Total03526061

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

CLEC10A · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

OMIM
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
Oncolytic adenovirus in treating malignant ascites: A phase II trial and longitudinal single-cell study.
Zhang Y et al.·Mol Ther
2024Clinical trial
High expression of CLEC10A in head and neck squamous cell carcinoma indicates favorable prognosis and high-level immune infiltration status.
Zou M et al.·Cell Immunol
2022
CLEC10A is a prognostic biomarker and correlated with clinical pathologic features and immune infiltrates in lung adenocarcinoma.
He M et al.·J Cell Mol Med
2021
Identification of CLEC10A as a human lectin for pancreatic ductal adenocarcinoma.
Tsukamoto S et al.·Sci Rep
2025
Plasma proteomic profiling reveals Parkinson's disease-associated proteins: A UK Biobank study.
Jiao X et al.·Parkinsonism Relat Disord
2025
Generation of cDC-like cells from human induced pluripotent stem cells via Notch signaling.
Makino K et al.·J Immunother Cancer
2022
Impact of endobronchial allergen provocation on macrophage phenotype in asthmatics.
Winkler C et al.·BMC Immunol
2014
Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients.
Zhu GQ et al.·J Transl Med
2019Cohort
Identification and validation of an immune-related gene signature predictive of overall survival in colon cancer.
Zhang X et al.·Aging (Albany NY)
2020
Polymorphism of transient axonal glycoprotein-1 in chronic inflammatory demyelinating polyneuropathy.
Iijima M et al.·J Peripher Nerv Syst
2011
Top 10 resultsSearch PubMed ↗
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Europe PMC
Top 5 resultsSearch Europe PMC ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →

External Resources

Links to major genomics databases and tools